Results 211 to 220 of about 180,190 (229)
Some of the next articles are maybe not open access.
The Cost-Effectiveness of Ranibizumab Treat and Extend Regimen Versus Aflibercept in the UK
Advances in Therapy, 2016Wet age-related macular degeneration (AMD) is a chronic eye condition that causes severe deterioration of vision and even blindness. Current wet AMD treatment in the UK involves the vascular endothelial growth factor inhibitors ranibizumab and aflibercept.
Wrik, Ghosh +6 more
openaire +2 more sources
Ophthalmic Surgery, Lasers and Imaging Retina, 2018
BACKGROUND AND OBJECTIVE: Compare fixed monthly dosing of ranibizumab to treat-and-extend (T&E) ranibizumab during a period of 24 months for diabetic macular edema (DME) treatment. PATIENTS AND METHODS: Single-center, randomized, prospective pilot study that included 20 eyes of ...
David A, Eichenbaum +3 more
openaire +2 more sources
BACKGROUND AND OBJECTIVE: Compare fixed monthly dosing of ranibizumab to treat-and-extend (T&E) ranibizumab during a period of 24 months for diabetic macular edema (DME) treatment. PATIENTS AND METHODS: Single-center, randomized, prospective pilot study that included 20 eyes of ...
David A, Eichenbaum +3 more
openaire +2 more sources
Graefe's Archive for Clinical and Experimental Ophthalmology, 2017
To evaluate the effects of aflibercept therapy using a treat-and-extend regimen on treatment-naïve polypoidal choroidal vasculopathy (PCV).In a retrospective interventional case series of 58 eyes of 58 patients with PCV, we assessed best-corrected visual acuity (BCVA), central macular thickness (CMT), central choroidal thickness (CCT), and number of ...
Dan, Călugăru, Mihai, Călugăru
openaire +4 more sources
To evaluate the effects of aflibercept therapy using a treat-and-extend regimen on treatment-naïve polypoidal choroidal vasculopathy (PCV).In a retrospective interventional case series of 58 eyes of 58 patients with PCV, we assessed best-corrected visual acuity (BCVA), central macular thickness (CMT), central choroidal thickness (CCT), and number of ...
Dan, Călugăru, Mihai, Călugăru
openaire +4 more sources
Graefe's Archive for Clinical and Experimental Ophthalmology, 2019
To assess the morphological and functional outcome and stability of the "treat and extend" protocol using aflibercept compared to ranibizumab for the treatment of eyes with neovascular age-related macular degeneration.This retrospective study included 100 eyes of 94 patients with primary onset neovascular age-related macular degeneration followed up ...
Alaa Din Abdin +4 more
openaire +2 more sources
To assess the morphological and functional outcome and stability of the "treat and extend" protocol using aflibercept compared to ranibizumab for the treatment of eyes with neovascular age-related macular degeneration.This retrospective study included 100 eyes of 94 patients with primary onset neovascular age-related macular degeneration followed up ...
Alaa Din Abdin +4 more
openaire +2 more sources
OUTCOMES OF TREAT-AND-EXTEND USING AFLIBERCEPT IN TYPE 3 MACULAR NEOVASCULARIZATION
RetinaPurpose: To evaluate the clinical outcomes of a treat-and-extend regimen using aflibercept for Type 3 macular neovascularization. Methods: In this prospective phase four clinical trial, 25 patients with Type 3 macular ...
Jae Hui Kim +3 more
openaire +1 more source
Clinical & Experimental Ophthalmology
AbstractBackgroundTo describe the incidence and pattern of reactivation of neovascular age‐related macular degeneration (nAMD) following successful treatment with treat‐and‐extend intravitreal anti‐vascular endothelial growth factor therapy.MethodsConsecutive patients with treated nAMD who did not require further treatment over a 6‐month period and who
Jose Carlo M. Artiaga +6 more
openaire +2 more sources
AbstractBackgroundTo describe the incidence and pattern of reactivation of neovascular age‐related macular degeneration (nAMD) following successful treatment with treat‐and‐extend intravitreal anti‐vascular endothelial growth factor therapy.MethodsConsecutive patients with treated nAMD who did not require further treatment over a 6‐month period and who
Jose Carlo M. Artiaga +6 more
openaire +2 more sources
Retina, 2016
To assess patterns and outcomes of a "Treat and Extend" dosing regimen of ranibizumab in patients with age-related macular degeneration.Three hundred and thirty two treatment-naive age-related macular degeneration patients starting therapy with ranibizumab between January 1, 2011, and June 30, 2012, at the Ivey Eye Institute were reviewed, and 79 met ...
Yufeng N, Chen +3 more
openaire +2 more sources
To assess patterns and outcomes of a "Treat and Extend" dosing regimen of ranibizumab in patients with age-related macular degeneration.Three hundred and thirty two treatment-naive age-related macular degeneration patients starting therapy with ranibizumab between January 1, 2011, and June 30, 2012, at the Ivey Eye Institute were reviewed, and 79 met ...
Yufeng N, Chen +3 more
openaire +2 more sources
Archivos de la Sociedad Española de Oftalmología (English Edition), 2017
To describe functional/morphological outcomes of treat-and-extend (TAE) with aflibercept in different subtypes of neovascularizations (CNV) secondary to exudative age-related macular degeneration (AMD).Retrospective study was conducted on 30 eyes of 30 patients treated with 2 mg-aflibercept according to a TAE protocol.
V, Castro-Navarro +3 more
openaire +2 more sources
To describe functional/morphological outcomes of treat-and-extend (TAE) with aflibercept in different subtypes of neovascularizations (CNV) secondary to exudative age-related macular degeneration (AMD).Retrospective study was conducted on 30 eyes of 30 patients treated with 2 mg-aflibercept according to a TAE protocol.
V, Castro-Navarro +3 more
openaire +2 more sources
RETINAL Cases & Brief Reports
Background/Purpose: This is a case report on providing amphotericin B for postoperative fungal endophthalmitis with a treat-and-extend schedule. This study explores a deviation from the typical standard of care, given the circumstances encountered by this patient.
Sparsh Jain, Roxana Godiwalla, Hart Moss
openaire +1 more source
Background/Purpose: This is a case report on providing amphotericin B for postoperative fungal endophthalmitis with a treat-and-extend schedule. This study explores a deviation from the typical standard of care, given the circumstances encountered by this patient.
Sparsh Jain, Roxana Godiwalla, Hart Moss
openaire +1 more source
Acta Ophthalmologica, 2019
AbstractPurposeTo optimize the aflibercept treat‐and‐extend protocol in wet age‐related macular degeneration (wAMD).MethodsA prospective randomized clinical trial consisting of 52 eyes from 52 patients with treatment‐naïve wAMD. Patients received three monthly aflibercept injections and were then randomized 1:1 to two different dosing protocols.
Taipale Claudia +7 more
openaire +2 more sources
AbstractPurposeTo optimize the aflibercept treat‐and‐extend protocol in wet age‐related macular degeneration (wAMD).MethodsA prospective randomized clinical trial consisting of 52 eyes from 52 patients with treatment‐naïve wAMD. Patients received three monthly aflibercept injections and were then randomized 1:1 to two different dosing protocols.
Taipale Claudia +7 more
openaire +2 more sources